



RCG RECEIVED
APR 29 2003
MAIL STOP AF
PATENT
2001 TECH CENTER 1600/2900

IN THE U.S. PATENT AND TRADEMARK OFFICE

application of: Amanda Johanne KILIAAN et al.
Conf.: 2164
Appl. No.: 09/703,798
Group: 1651
Filed: November 2, 2000
Examiner: Ruth A Davis
Title: PREPARATION FOR THE PREVENTION AND/OR
TREATMENT OF VASCULAR DISORDERS

HJD
6-19-03

REQUEST FOR CONTINUED EXAMINATION
UNDER 37 C.F.R. § 1.114

Assistant Commissioner for Patents
Washington, DC 20231

April 24, 2003

Sir:

This is a "Request for Continued Examination" under 37 C.F.R. § 1.114, the provisions of which do not apply to:

(1) A provisional application; (2) An application for a utility or plant patent filed under 35 U.S.C. 111(a) before June 8, 1995; (3) An international application filed under 35 U.S.C. §363 before June 8, 1995; (4) An application for a design patent; or (5) A patent under reexamination.

This Request for Continued Examination is being filed prior to the earliest of:

(1) Payment of the issue fee, unless a petition under §1.313 is granted; (2) Abandonment of the application; or (3) The filing of a notice of appeal to the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. § 141, or the commencement of civil action under 35 U.S.C. §§ 145 or 146, unless the appeal or civil action is terminated.

The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

The enclosed document is being transmitted via facsimile.

Submission Required under 37 C.F.R. § 1.114:

Enter as part of the present submission:

An After Final Amendment previously filed on , under 37 C.F.R. § 1.116 but unentered, in the present application.

- Arguments in the Appeal Brief or Reply Brief previously filed on .
- A Reply Under Rule 1.111, attached hereto. Claim fee(s) are calculated as set forth below:

	TOTAL NUMBER OF CLAIMS PREVIOUSLY FILED	TOTAL NUMBER OF CLAIMS BEING FILED HEREWITH	NUMBER EXTRA	RATE	FEE
Total Claims				x\$18 =	\$0.00
Independent Claims				x\$84 =	\$0.00
TOTAL CLAIM FEE(S)					\$0.00

- An Information Disclosure Statement (IDS) and PTO-1449 form(s) is/are attached hereto for the Examiner's consideration.
- Other:
- Fees**

The required fee under 37 C.F.R. § 1.17(e) as required by 37 C.F.R. § 1.114 when the RCE is filed, is enclosed herewith:

 - \$375.00 - small entity
 - \$750.00 - large entity- The applicant(s) hereby petition(s) for an extension of () month(s) pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). The fee has been calculated as shown below:
 - NO extensions of time have been previously obtained in the prior application. Thus, a fee of \$0.00 is required for the full period of the above-requested extension of time.
 - An extension of () month(s) was previously requested and paid for on in the instant application. Thus, a fee of \$0.00 is required to obtain an additional () month(s) extension.
- Enclosed is a check in the amount of \$750.00 for the applicable filing fee, additional claims fee, and/or extension fees.
- Please charge Deposit Account No. 25-0120 in the amount of \$0.00. A triplicate copy of this sheet is attached.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

Philip A. DuBois

Philip A. DuBois, Reg. No. 50,696

745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297

PD/fb

Attachments

Revised 0/0/0000

RECEIVED

APR 29 2003

Atty. Docket No. 2001-1165

TECH CENTER 1600/2900
PATENTS



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Amanda Johanne KILIAAN et al. Confirmation No. 2164

Serial No. 09/703,798 GROUP 1651

Filed November 2, 2000 Examiner Ruth A Davis

PREPARATION FOR THE PREVENTION
AND/OR TREATMENT OF VASCULAR
DISORDERS

AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Official Action of August 22, 2002,
please amend the above-identified application as follows:

IN THE CLAIMS:

Amend claim 19 as follows:

19. (amended) A preparation for the prevention/treatment of dementia syndromes, cognitive degeneration or hearing loss, comprising the following fractions:

B B
fraction a) consisting of long chain polyunsaturated fatty acids containing at least one member selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), dihomogammalinolenic acid (DHGLA), arachidonic acid (AA), linoleic acid and α -linoleic acid, wherein the ratio of the total amount of EPA + DHA + DHGLA + AA to the total amount of